

Elisabetta Bugianesi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2635016/publications.pdf>

Version: 2024-02-01

147
papers

23,301
citations

18482

62
h-index

8866

145
g-index

152
all docs

152
docs citations

152
times ranked

20690
citing authors

#	ARTICLE	IF	CITATIONS
1	Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach?. Gut, 2022, 71, 382-390.	12.1	113
2	Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. Gut, 2022, 71, 1006-1019.	12.1	195
3	A Global Survey of Physicians Knowledge About Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 2022, 20, e1456-e1468.	4.4	49
4	Hepatocyte-Specific Deletion of HIF2Î± Prevents NASH-Related Liver Carcinogenesis by Decreasing Cancer Cell Proliferation. Cellular and Molecular Gastroenterology and Hepatology, 2022, 13, 459-482.	4.5	13
5	Clinical and Patient-Reported Outcomes From Patients With Nonalcoholic Fatty Liver Disease Across the World: Data From the Global Non-Alcoholic Steatohepatitis (NASH)/ Non-Alcoholic Fatty Liver Disease (NAFLD) Registry. Clinical Gastroenterology and Hepatology, 2022, 20, 2296-2306.e6.	4.4	35
6	Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance. JHEP Reports, 2022, 4, 100409.	4.9	20
7	The EASLâ€“Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. Lancet, The, 2022, 399, 61-116.	13.7	257
8	Derivation and validation of the nonalcoholic fatty liver disease cirrhosis score (NCS) to distinguish bridging fibrosis from cirrhosis. European Journal of Internal Medicine, 2022, 98, 53-60.	2.2	4
9	Crosstalk between Irisin Levels, Liver Fibrogenesis and Liver Damage in Non-Obese, Non-Diabetic Individuals with Non-Alcoholic Fatty Liver Disease. Journal of Clinical Medicine, 2022, 11, 635.	2.4	12
10	Oncostatin <scp>M</scp> is overexpressed in <scp>NASH</scp>â€“related hepatocellular carcinoma and promotes cancer cell invasiveness and angiogenesis. Journal of Pathology, 2022, 257, 82-95.	4.5	12
11	Macrophage scavenger receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease. Journal of Hepatology, 2022, 76, 1001-1012.	3.7	54
12	Clinical Application of Droplet Digital PCR for Hepatitis Delta Virus Quantification. Biomedicines, 2022, 10, 792.	3.2	4
13	A cholestatic pattern predicts major liverâ€“related outcomes in patients with nonâ€“alcoholic fatty liver disease. Liver International, 2022, 42, 1037-1048.	3.9	4
14	Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles. Hepatology, 2022, 76, 1121-1134.	7.3	31
15	Rare ATG7 genetic variants predispose patients to severe fatty liver disease. Journal of Hepatology, 2022, 77, 596-606.	3.7	38
16	An international survey on patterns of practice in NAFLD and expectations for therapiesâ€“The POPâ€“NEXT project. Hepatology, 2022, 76, 1766-1777.	7.3	7
17	Global multi-stakeholder endorsement of the MAFLD definition. The Lancet Gastroenterology and Hepatology, 2022, 7, 388-390.	8.1	135
18	Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease. JHEP Reports, 2022, 4, 100477.	4.9	31

#	ARTICLE	IF	CITATIONS
19	A nutrigenetic tool for precision dietary management of non-alcoholic fatty liver disease deeming insulin resistance markers. <i>Panminerva Medica</i> , 2022, 64, .	0.8	5
20	NAFLD/NASH. <i>Journal of Hepatology</i> , 2022, 77, 549-550.	3.7	10
21	Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 638-651.	17.8	69
22	Current therapies and new developments in NASH. <i>Gut</i> , 2022, 71, 2123-2134.	12.1	82
23	Diagnostic scores and scales for appraising Nonalcoholic fatty liver disease and omics perspectives for precision medicine. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2022, 25, 285-291.	2.5	5
24	Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 806-815.e5.	4.4	90
25	Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores. <i>Journal of Hepatology</i> , 2021, 74, 775-782.	3.7	193
26	The Clinical Role of Serum Epidermal Growth Factor Receptor 3 in Hepatitis C Virus-Infected Patients with Early Hepatocellular Carcinoma. <i>Biology</i> , 2021, 10, 215.	2.8	4
27	Insulin Resistance across the Spectrum of Nonalcoholic Fatty Liver Disease. <i>Metabolites</i> , 2021, 11, 155.	2.9	44
28	NASH limits anti-tumour surveillance in immunotherapy-treated HCC. <i>Nature</i> , 2021, 592, 450-456.	27.8	649
29	Association between gut permeability and insulin resistance: Any role for zonulin in patients with non-alcoholic fatty liver disease?. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101611.	1.5	0
30	Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: A cost-of-illness analysis. <i>Liver International</i> , 2021, 41, 1227-1242.	3.9	76
31	Inflammatory Bowel Disease Nurseâ€”Practical Messages. <i>Nursing Reports</i> , 2021, 11, 229-241.	2.1	8
32	Biomarkers of Oncogenesis, Adipose Tissue Dysfunction and Systemic Inflammation for the Detection of Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease. <i>Cancers</i> , 2021, 13, 2305.	3.7	24
33	Natural history of NASH. <i>Liver International</i> , 2021, 41, 78-82.	3.9	16
34	Switching from Biosimilar to Biosimilar Adalimumab, Including Multiple Switching, in Crohnâ€™s Disease: A Prospective Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 3387.	2.4	16
35	Outcomes and potential surrogate markers for future clinical trials of non-alcoholic steatohepatitis cirrhosis. <i>Liver International</i> , 2021, 41, 1999-2008.	3.9	7
36	Risk Factors of Urothelial Cancer in Inflammatory Bowel Disease. <i>Journal of Clinical Medicine</i> , 2021, 10, 3257.	2.4	2

#	ARTICLE	IF	CITATIONS
37	Copy number variation and expression of exportin-4 associates with severity of fibrosis in metabolic associated fatty liver disease. <i>EBioMedicine</i> , 2021, 70, 103521.	6.1	11
38	Differences between current clinical guidelines for screening, diagnosis and management of nonalcoholic fatty liver disease and real-world practice: a targeted literature review. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 1253-1266.	3.0	9
39	Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2021, 161, 1657-1669.	1.3	229
40	Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2021, 75, 786-794.	3.7	100
41	Management of non-alcoholic fatty liver disease. <i>BMJ, The</i> , 2021, 372, m4747.	6.0	99
42	Efficacy of a Preparation Based on Calcium Butyrate, <i>Bifidobacterium bifidum</i> , <i>Bifidobacterium lactis</i> , and Fructooligosaccharides in the Prevention of Relapse in Ulcerative Colitis: A Prospective Observational Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 4961.	2.4	8
43	The Impact of Dysmetabolic Sarcopenia Among Insulin Sensitive Tissues: A Narrative Review. <i>Frontiers in Endocrinology</i> , 2021, 12, 716533.	3.5	27
44	Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation. <i>Hepatology</i> , 2020, 71, 1213-1227.	7.3	209
45	qFIBS: An Automated Technique for Quantitative Evaluation of Fibrosis, Inflammation, Ballooning, and Steatosis in Patients With Nonalcoholic Steatohepatitis. <i>Hepatology</i> , 2020, 71, 1953-1966.	7.3	66
46	Oncostatin M, A Profibrogenic Mediator Overexpressed in Non-Alcoholic Fatty Liver Disease, Stimulates Migration of Hepatic Myofibroblasts. <i>Cells</i> , 2020, 9, 28.	4.1	26
47	Prognostic Role of Serum Cytokeratin-19 Fragment (CYFRA 21-1) in Patients with Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 2776.	3.7	14
48	The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease. <i>Contemporary Clinical Trials</i> , 2020, 98, 106175.	1.8	71
49	Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	205
50	Interplay between Oxidative Stress and Metabolic Derangements in Non-Alcoholic Fatty Liver Disease: The Role of Selenoprotein P. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8838.	4.1	22
51	Clinical Response and Changes of Cytokines and Zonulin Levels in Patients with Diarrhoea-Predominant Irritable Bowel Syndrome Treated with <i>Bifidobacterium Longum</i> ES1 for 8 or 12 Weeks: A Preliminary Report. <i>Journal of Clinical Medicine</i> , 2020, 9, 2353.	2.4	18
52	Presence of Serum Antinuclear Antibodies Does Not Impact Long-Term Outcomes in Nonalcoholic Fatty Liver Disease. <i>American Journal of Gastroenterology</i> , 2020, 115, 1289-1292.	0.4	9
53	Macrophage Markers Do Not Add to the Prediction of Liver Fibrosis by Transient Elastography in Patients With Metabolic Associated Fatty Liver Disease. <i>Frontiers in Medicine</i> , 2020, 7, 616212.	2.6	2
54	The Usefulness of Microencapsulated Sodium Butyrate Add-On Therapy in Maintaining Remission in Patients with Ulcerative Colitis: A Prospective Observational Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 3941.	2.4	34

#	ARTICLE	IF	CITATIONS
55	Alpha-Fetoprotein, Protein Induced by Vitamin K Absence or Antagonist II and Glypican-3 for the Detection and Prediction of Hepatocellular Carcinoma in Patients with Cirrhosis of Viral Etiology. <i>Cancers</i> , 2020, 12, 3218.	3.7	27
56	Serum Interleukin-6 and -8 as Predictors of Response to Vedolizumab in Inflammatory Bowel Diseases. <i>Journal of Clinical Medicine</i> , 2020, 9, 1323.	2.4	20
57	Mechanisms for increased risk of diabetes in chronic liver diseases. <i>Liver International</i> , 2020, 40, 2489-2499.	3.9	9
58	On-Treatment Decrease of Serum Interleukin-6 as a Predictor of Clinical Response to Biologic Therapy in Patients with Inflammatory Bowel Diseases. <i>Journal of Clinical Medicine</i> , 2020, 9, 800.	2.4	29
59	Fatty liver disease: putting the spotlight on a silent menace for young adults. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 236-238.	8.1	9
60	Analytical and clinical evaluation of a novel assay for anti-HBc IgG measurement in serum of subjects with overt and occult HBV infection. <i>Diagnostic Microbiology and Infectious Disease</i> , 2020, 96, 114985.	1.8	14
61	A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. <i>Journal of Hepatology</i> , 2020, 73, 202-209.	3.7	2,171
62	Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort. <i>Journal of Hepatology</i> , 2020, 73, 505-515.	3.7	279
63	Genetic variation in the TLL1 gene is not associated with fibrosis in patients with metabolic associated fatty liver disease. <i>PLoS ONE</i> , 2020, 15, e0243590.	2.5	3
64	Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 748-755.e3.	4.4	559
65	Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2019, 71, 1012-1021.	3.7	128
66	Adalimumab Therapy Improves Intestinal Dysbiosis in Crohn's Disease. <i>Journal of Clinical Medicine</i> , 2019, 8, 1646.	2.4	50
67	The next decade of metabolism. <i>Nature Metabolism</i> , 2019, 1, 2-4.	11.9	8
68	Prevalence and long-term outcomes of non-alcoholic fatty liver disease among elderly individuals from the United States. <i>BMC Gastroenterology</i> , 2019, 19, 56.	2.0	65
69	Rare Pathogenic Variants Predispose to Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. <i>Scientific Reports</i> , 2019, 9, 3682.	3.3	85
70	Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2310-2319.e6.	4.4	66
71	A variant in the MICA gene is associated with liver fibrosis progression in chronic hepatitis C through TGF- β 1 dependent mechanisms. <i>Scientific Reports</i> , 2019, 9, 1439.	3.3	7
72	Effects of Alcohol Consumption and Metabolic Syndrome on Mortality in Patients With Nonalcoholic and Alcohol-Related Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1625-1633.e1.	4.4	107

#	ARTICLE	IF	CITATIONS
73	Altered Metabolic Profile and Adipocyte Insulin Resistance Mark Severe Liver Fibrosis in Patients with Chronic Liver Disease. <i>International Journal of Molecular Sciences</i> , 2019, 20, 6333.	4.1	24
74	Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2019, 394, 2184-2196.	13.7	818
75	Impact of Obesity and Alanine Aminotransferase Levels on the Diagnostic Accuracy for Advanced Liver Fibrosis of Noninvasive Tools in Patients With Nonalcoholic Fatty Liver Disease. <i>American Journal of Gastroenterology</i> , 2019, 114, 916-928.	0.4	57
76	Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. <i>Hepatology</i> , 2019, 69, 2672-2682.	7.3	1,203
77	A spotlight on pathogenesis, interactions and novel therapeutic options in NAFLD. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 80-82.	17.8	29
78	NASH in Lean Individuals. <i>Seminars in Liver Disease</i> , 2019, 39, 086-095.	3.6	161
79	A polymorphism in the Irisin-encoding gene (FNDC5) associates with hepatic steatosis by differential miRNA binding to the 3'UTR. <i>Journal of Hepatology</i> , 2019, 70, 494-500.	3.7	67
80	Clinical outcomes in chronic hepatitis C long-term responders to pre-direct antiviral agents: a single-center retrospective study. <i>Minerva Medica</i> , 2019, 110, 401-409.	0.9	22
81	Hypoxia-inducible factor 2 α drives nonalcoholic fatty liver progression by triggering hepatocyte release of histidine-rich glycoprotein. <i>Hepatology</i> , 2018, 67, 2196-2214.	7.3	66
82	Reply to "Definition of Small for Gestational Age and Low Birthweight". <i>American Journal of Gastroenterology</i> , 2018, 113, 442.	0.4	0
83	Significant improvement of glycemic control in diabetic patients with HCV infection responding to direct-acting antiviral agents. <i>Journal of Medical Virology</i> , 2018, 90, 320-327.	5.0	80
84	Usefulness of the index of <sc>NASH</sc> " <sc>ION</sc> for the diagnosis of steatohepatitis in patients with non-alcoholic fatty liver: An external validation study. <i>Liver International</i> , 2018, 38, 715-723.	3.9	22
85	Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018, 15, 11-20.	17.8	3,487
86	Reply. <i>Hepatology</i> , 2018, 67, 1178-1180.	7.3	0
87	Should we undertake surveillance for HCC in patients with NAFLD?. <i>Journal of Hepatology</i> , 2018, 68, 326-334.	3.7	145
88	Altered amino acid concentrations in NAFLD: Impact of obesity and insulin resistance. <i>Hepatology</i> , 2018, 67, 145-158.	7.3	296
89	The Impact of Metabolic Syndrome on the Outcome of NASH: Cirrhosis, Hepatocellular Carcinoma, and Mortality. <i>Current Hepatology Reports</i> , 2018, 17, 336-344.	0.9	2
90	An internet-based approach for lifestyle changes in patients with NAFLD: Two-year effects on weight loss and surrogate markers. <i>Journal of Hepatology</i> , 2018, 69, 1155-1163.	3.7	80

#	ARTICLE	IF	CITATIONS
91	Non-invasive prediction of esophageal varices by stiffness and platelet in non-alcoholic fatty liver disease cirrhosis. <i>Journal of Hepatology</i> , 2018, 69, 878-885.	3.7	113
92	Metabolic syndrome and severity of fibrosis in nonalcoholic fatty liver disease: An age-dependent risk profiling study. <i>Liver International</i> , 2017, 37, 1389-1396.	3.9	44
93	IFN- γ 3, not IFN- γ 4, likely mediates IFNL3-IFNL4 haplotype-dependent hepatic inflammation and fibrosis. <i>Nature Genetics</i> , 2017, 49, 795-800.	21.4	86
94	Low Birthweight Increases the Likelihood of Severe Steatosis in Pediatric Non-Alcoholic Fatty Liver Disease. <i>American Journal of Gastroenterology</i> , 2017, 112, 1277-1286.	0.4	38
95	Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease. <i>Cancer Medicine</i> , 2017, 6, 1930-1940.	2.8	43
96	Use of HOMA-IR to diagnose non-alcoholic fatty liver disease: a population-based and inter-laboratory study. <i>Diabetologia</i> , 2017, 60, 1873-1882.	6.3	85
97	MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals. <i>Scientific Reports</i> , 2017, 7, 4492.	3.3	193
98	Nonalcoholic fatty liver disease: Updates on associations with the metabolic syndrome and lipid profile and effects of treatment with PPAR- γ agonists. <i>Metabolism: Clinical and Experimental</i> , 2017, 66, 64-68.	3.4	17
99	Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis. <i>American Journal of Gastroenterology</i> , 2017, 112, 740-751.	0.4	524
100	Microvesicles released from fat-laden cells promote activation of hepatocellular NLRP3 inflammasome: A pro-inflammatory link between lipotoxicity and non-alcoholic steatohepatitis. <i>PLoS ONE</i> , 2017, 12, e0172575.	2.5	49
101	Pathophysiology of Non Alcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , 2016, 17, 2082.	4.1	126
102	Different Serum Free Fatty Acid Profiles in NAFLD Subjects and Healthy Controls after Oral Fat Load. <i>International Journal of Molecular Sciences</i> , 2016, 17, 479.	4.1	70
103	Non-Alcoholic Fatty Liver Disease and Extra-Hepatic Cancers. <i>International Journal of Molecular Sciences</i> , 2016, 17, 717.	4.1	158
104	Renin-Angiotensin System Inhibitors, Type 2 Diabetes and Fibrosis Progression: An Observational Study in Patients with Nonalcoholic Fatty Liver Disease. <i>PLoS ONE</i> , 2016, 11, e0163069.	2.5	63
105	Peripheral insulin resistance predicts liver damage in nondiabetic subjects with nonalcoholic fatty liver disease. <i>Hepatology</i> , 2016, 63, 107-116.	7.3	67
106	Cytokeratin 18-Aspartate396 apoptotic fragment for fibrosis detection in patients with non-alcoholic fatty liver disease and chronic viral hepatitis. <i>Digestive and Liver Disease</i> , 2016, 48, 55-61.	0.9	19
107	EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease: disease mongering or call to action?. <i>Diabetologia</i> , 2016, 59, 1145-1147.	6.3	15
108	Reply to "Chronic hepatitis C and diabetes: More questions than answers with the new direct acting antiviral drugs". <i>Digestive and Liver Disease</i> , 2016, 48, 1101-1102.	0.9	0

#	ARTICLE	IF	CITATIONS
109	Nonalcoholic fatty liver disease: cause or consequence of type 2 diabetes?. Liver International, 2016, 36, 1563-1579.	3.9	126
110	Childhood obesity: time bomb for future burden of chronic liver disease. Nature Reviews Gastroenterology and Hepatology, 2016, 13, 506-507.	17.8	4
111	MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C. Nature Communications, 2016, 7, 12757.	12.8	104
112	Imaging biomarkers for steatohepatitis and fibrosis detection in non-alcoholic fatty liver disease. Scientific Reports, 2016, 6, 31421.	3.3	33
113	The macrophage activation marker <scp>sCD</scp> 163 is associated with morphological disease stages in patients with nonalcoholic fatty liver disease. Liver International, 2016, 36, 1549-1557.	3.9	94
114	Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes. Hepatology, 2016, 64, 34-46.	7.3	83
115	FibroGENE: A gene-based model for staging liver fibrosis. Journal of Hepatology, 2016, 64, 390-398.	3.7	64
116	MERTK rs4374383 polymorphism affects the severity of fibrosis in non-alcoholic fatty liver disease. Journal of Hepatology, 2016, 64, 682-690.	3.7	106
117	Treatment of type 2 diabetes mellitus by viral eradication in chronic hepatitis C: Myth or reality?. Digestive and Liver Disease, 2016, 48, 105-111.	0.9	54
118	A "systems medicine" approach to the study of non-alcoholic fatty liver disease. Digestive and Liver Disease, 2016, 48, 333-342.	0.9	56
119	Progression and Natural History of Nonalcoholic Fatty Liver Disease in Adults. Clinics in Liver Disease, 2016, 20, 313-324.	2.1	120
120	Liver Cancer: Connections with Obesity, Fatty Liver, and Cirrhosis. Annual Review of Medicine, 2016, 67, 103-117.	12.2	535
121	Nonalcoholic fatty liver disease. Nature Reviews Disease Primers, 2015, 1, 15080.	30.5	612
122	Risk of microangiopathy in type 2 diabetes mellitus patients with or without chronic hepatitis C: Results of a retrospective long-term controlled cohort study. Digestive and Liver Disease, 2015, 47, 405-410.	0.9	9
123	Interferon-Î» rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease. Nature Communications, 2015, 6, 6422.	12.8	156
124	Systemic Complications of Nonalcoholic Fatty Liver Disease: When the Liver Is Not an Innocent Bystander. Seminars in Liver Disease, 2015, 35, 236-249.	3.6	66
125	Ovarian senescence increases liver fibrosis in humans and zebrafish with steatosis. DMM Disease Models and Mechanisms, 2015, 8, 1037-46.	2.4	52
126	The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease. Liver International, 2015, 35, 1566-1573.	3.9	116

#	ARTICLE	IF	CITATIONS
127	Carbohydrate intake and nonalcoholic fatty liver disease: fructose as a weapon of mass destruction. <i>Hepatobiliary Surgery and Nutrition</i> , 2015, 4, 109-16.	1.5	96
128	Serum Ferritin Levels Lack Diagnostic Accuracy for Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1163-1169.e1.	4.4	41
129	NAFLD and Hepatocellular Carcinoma: How Big a Problem is This Really?. <i>Current Hepatology Reports</i> , 2014, 13, 113-118.	0.9	4
130	379 Characteristics and Long-Term Prognosis of Lean Patients With Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2014, 146, S-909.	1.3	94
131	Glucokinase Regulatory Protein Gene Polymorphism Affects Liver Fibrosis in Non-Alcoholic Fatty Liver Disease. <i>PLoS ONE</i> , 2014, 9, e87523.	2.5	112
132	Non-Alcoholic Fatty Liver Disease (NAFLD) and Its Connection with Insulin Resistance, Dyslipidemia, Atherosclerosis and Coronary Heart Disease. <i>Nutrients</i> , 2013, 5, 1544-1560.	4.1	648
133	Hepatic and Cardiac Steatosis. <i>Heart Failure Clinics</i> , 2012, 8, 663-670.	2.1	19
134	Reliability of transient elastography for the detection of fibrosis in Non-Alcoholic Fatty Liver Disease and chronic viral hepatitis. <i>Journal of Hepatology</i> , 2011, 54, 64-71.	3.7	230
135	Complex noninvasive fibrosis models are more accurate than simple models in nonalcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 1536-1543.	2.8	145
136	HBV and HCV infection in type 2 diabetes mellitus: a survey in three diabetes units in different Italian areas. <i>Acta Diabetologica</i> , 2011, 48, 337-343.	2.5	22
137	Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C. <i>Hepatology</i> , 2009, 50, 697-706.	7.3	140
138	NASH and the risk of cirrhosis and hepatocellular carcinoma in type 2 diabetes. <i>Current Diabetes Reports</i> , 2007, 7, 175-180.	4.2	56
139	Reply:. <i>Hepatology</i> , 2006, 43, 1168-1169.	7.3	18
140	Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin resistance and hepatic steatosis. <i>Hepatology</i> , 2006, 44, 1648-1655.	7.3	137
141	Insulin resistance: A metabolic pathway to chronic liver disease. <i>Hepatology</i> , 2005, 42, 987-1000.	7.3	730
142	Plasma Adiponectin in Nonalcoholic Fatty Liver Is Related to Hepatic Insulin Resistance and Hepatic Fat Content, Not to Liver Disease Severity. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 3498-3504.	3.6	370
143	A Randomized Controlled Trial of Metformin versus Vitamin E or Prescriptive Diet in Nonalcoholic Fatty Liver Disease. <i>American Journal of Gastroenterology</i> , 2005, 100, 1082-1090.	0.4	631
144	Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. <i>Hepatology</i> , 2004, 39, 179-187.	7.3	394

#	ARTICLE	IF	CITATIONS
145	Uric acid levels and liver fibrosis in nonalcoholic fatty liver disease. Hepatology, 2004, 39, 1749-1749.	7.3	7
146	Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): treatment. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2004, 18, 1105-1116.	2.4	32
147	Expanding the natural history of nonalcoholic steatohepatitis: From cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology, 2002, 123, 134-140.	1.3	1,332